NCT04743375

Clinical Efficacy of Silk Sericin Dressing With Collagen for Split-thickness Skin Graft Donor Site Treatment

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Chulalongkorn University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To examine the efficacy and safety of sericin dressing with collagen in STSG donor site treatment comparing with Bactigras®. Around 30 patients will be enrolled in this study.

Detailed description

Wounds are a public health problem found worldwide that associated with both clinical and economic burdens. Although several wound dressings are available, some limitations of those dressings still existed resulting in the need for new wound dressing development. The sericin dressing with collagen was developed to provide a moist environment and bioactive ingredients to the wound bed. To evaluate its efficacy and safety, the STSG donor sites of each patient will be divided into two equal areas. Each area will be randomly allocated into sericin dressing with collagen group or control group (Bactigras®). The outcomes will be collected to examine the efficacy and safety of sericin dressing with collagen in comparison with commercial dressing Bactigras®.

Conditions

• Wound Heal
• Wound Surgical
• Donor Site Complication

Interventions

Type	Name	Description
OTHER	wound dressing application	Sericin dressing with collagen or Bactigras will be used as a primary dressing for treating the STSG donor site.

Timeline

• Start date: 2021-02-01
• Primary completion: 2021-07-01
• Completion: 2021-12-01
• First posted: 2021-02-08
• Last updated: 2021-02-08

Locations

1 site across 1 country: Thailand